Dipti Talaulikar
Experienced in Secondary Immunodeficiency (SID)

Dipti Talaulikar

Canberra, ACT, AU 
Experienced in Secondary Immunodeficiency (SID)
Canberra, ACT, AU 
OverviewLocationsClinical Research

Overview

Dipti Talaulikar practices in Canberra, Australia. Ms. Talaulikar is rated as an Experienced expert by MediFind in the treatment of Secondary Immunodeficiency (SID). Her top areas of expertise are Waldenstrom Macroglobulinemia, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 90 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Secondary Immunodeficiency (SID).

Gender
Female

Locations

Canberra, ACT, Australia
Other Locations
Australian Capital Territory, Australia
Sydney, NSW, Australia
Garran, ACT, Australia
Acton, ACT, Australia
Melbourne, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drugs: BGB-3111 (Zanubrutinib), Ibrutinib
Study Phase: Phase 3

90 Total Publications

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific advisory group of Australia (MSAG) to myeloma australia.
Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific advisory group of Australia (MSAG) to myeloma australia.
Journal: Expert review of hematology
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Talaulikar's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile